Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients

Tokudome, Nahomi; Ito, Yoshiaki; Takahashi, Shunji; Kobayashi, Kokoro; Taira, Shinichiro; Tsutsumi, Chizuko; Oto, Masafumi; Oba, Masaru; Inoue, Kentaro; Kuwayama, A; Masumura, Kyoko; Nakayama, Yasunori; Watanabe, Chie; Hatake, Kiyohiko

doi:10.1007/s12282-011-0259-4

Cited by 13 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, 50 studies were eligible for meta-analysis (Fig. 1)4591112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657.…”

Section: Resultsmentioning

confidence: 99%

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Yan

Cui

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Whether circulating tumor cells (CTCs) can be used as an indicator of treatment response in breast cancer (BC) needs to be clarified. We addressed this issue by a meta-analysis. PubMed, EMBase and Cochrane library databases were searched in June 2016. Effect measures were estimated as pooled risk ratio (RR), odds ratio (OR) or mean difference by fixed- or random-effect models, according to heterogeneity of included studies. In total, 50 studies with 6712 patients were recruited. Overall analysis showed that there was a significant reduction of CTC-positive rate (RR = 0.68, 95% CI: 0.61–0.76, P < 0.00001) after treatment. Subgroup analyses revealed that neoadjuvant treatment, adjuvant treatment, metastatic treatment or combination therapy could reduce the CTC-positive rate, but surgery could not; moreover, the reduction was only found in HER2+ or HER2- patients but not in the triple-negative ones. Reduction of CTC-positive rate was associated with lower probability of disease progression (OR = 0.54, 95% CI: 0.33–0.89, P = 0.01) and longer overall survival period (mean difference = 11.61 months, 95% CI: 8.63–14.59, P < 0.00001) as well as longer progression-free survival period (mean difference = 5.07 months, 95% CI: 2.70–7.44, P < 0.0001). These results demonstrate that CTC status can serve as an indicator to monitor the effectiveness of treatments and guide subsequent therapies in BC.

show abstract

“…Finally, 50 studies were eligible for meta-analysis (Fig. 1)4591112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657.…”

Section: Resultsmentioning

confidence: 99%

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Yan

Cui

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Tokudome and colleagues determined the presence of CTCs with the CellSearch System in 28 metastatic breast cancers. Nine of 28 patients (32%) had ≥ 5 CTCs before starting a new treatment and 2–3 months after starting chemotherapy, 5 of 23 patients (22%) had ≥ 5 CTCs per 7.5 ml of blood ( 35 ). Trastuzumab could decrease the frequency of CK-19 positive cells to undetectable levels in 28 out of 30 treated patients or after surgery ( 36 ).…”

Section: Discussionmentioning

confidence: 99%

P0023 Expression of CK-19 in circulating tumour cells from women with metastatic breast cancer

Soltani

Mokarian

Panjehpour

2015

European Journal of Cancer

View full text Add to dashboard Cite

“…The relationship between low BMI and higher cancer mortality risk might be at least partly explained by the presence of circulating tumor cells (CTCs) in the peripheral blood of patients [40]. CTCs are derived from clones in the primary tumor [41] and are thought to become scattered to various organs, leading to the development of distant metastasis [42]. In patients showing chronic undernutrition, cytokine reactions and subsequent activation of the immune system are compromised, which might affect the tumor-immune system interaction in distant organs [43].…”

Section: Discussionmentioning

confidence: 99%

Body mass index and survival after breast cancer diagnosis in Japanese women

et al. 2012

View full text Add to dashboard Cite

BackgroundBody mass index (BMI) may be an important factor affecting breast cancer outcome. Studies conducted mainly in Western countries have reported a relationship between higher BMI and a higher risk of all-cause death or breast cancer-specific death among women with breast cancer, but only a few studies have been reported in Japan so far. In the present prospective study, we investigated the associations between BMI and the risk of all-cause and breast cancer-specific death among breast cancer patients overall and by menopausal status and hormone receptor status.MethodsThe study included 653 breast cancer patients admitted to a single hospital in Japan, between 1997 and 2005. BMI was assessed using a self-administered questionnaire. The patients were completely followed up until December, 2008. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated according to quartile points of BMI categories, respectively: <21.2, ≥21.2 to <23.3 (reference), ≥23.3 to <25.8 and ≥25.8 kg/m2.ResultsDuring the follow-up period, 136 all-cause and 108 breast cancer-specific deaths were observed. After adjustment for clinical and confounding factors, higher BMI was associated with an increased risk of all-cause death (HR = 2.61; 95% CI: 1.01–6.78 for BMI ≥25.8 vs. ≥21.2 to <23.3 kg/m2) among premenopausal patients. According to hormonal receptor status, BMI ≥25.8 kg/m2 was associated with breast cancer-specific death (HR = 4.95; 95% CI: 1.05–23.35) and BMI <21.2 kg/m2 was associated with all-cause (HR = 2.91; 95% CI: 1.09–7.77) and breast cancer-specific death (HR = 7.23; 95% CI: 1.57–33.34) among patients with ER + or PgR + tumors. Analysis by hormonal receptor status also showed a positive association between BMI and mortality risk among patients with ER + or PgR + tumors and with BMI ≥21.2 kg/m2 (p for trend: 0.020 and 0.031 for all-cause and breast cancer-specific death, respectively).ConclusionsOur results suggest that both higher BMI and lower BMI are associated with an increased risk of mortality, especially among premenopausal patients or among patients with hormonal receptor positive tumors. Breast cancer patients should be informed of the potential importance of maintaining an appropriate body weight after they have been diagnosed.

show abstract

Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients

Abstract: We suggest that monitoring the number of CTCs may be helpful in predicting the efficacy of the treatment and the prognosis. CTCs might be especially useful with patients whose lesions are difficult to assess.

Cited by 13 publications

References 8 publications

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

P0023 Expression of CK-19 in circulating tumour cells from women with metastatic breast cancer

Body mass index and survival after breast cancer diagnosis in Japanese women

Contact Info

Product

Resources

About